<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04595864</url>
  </required_header>
  <id_info>
    <org_study_id>v1.0 20101014</org_study_id>
    <nct_id>NCT04595864</nct_id>
  </id_info>
  <brief_title>Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation</brief_title>
  <official_title>Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatocellular carcinoma (HCC) is the second commonest cause of cancer death worldwide. Liver&#xD;
      transplantation (LT) is the best curative treatment of HCC meeting Milan/UCSF criteria. Milan&#xD;
      (solitary tumour &lt;5cm, or up to 3 tumours, each &lt;3cm) and University of California San&#xD;
      Francisco (UCSF) criteria (solitary tumour ≤6.5cm, up to 3 tumours with none &gt;4.5cm, and&#xD;
      total tumour diameter ≤8cm) provide the benchmark requirements for LT, at which a 5-year&#xD;
      survival of &gt;70% and recurrence rate ranging from 5-15% can be achieved.&#xD;
&#xD;
      Recently, FOLFOX (Oxaliplatin and 5-fluorouracil) based hepatic artery infusion chemotherapy&#xD;
      (HAIC) exhibited high response rate for advanced HCC. Neo-adjuvant TAI for the HCC patients&#xD;
      with beyond criteria serving as a down-staging method for the advanced HCC to meet Milan/UCSF&#xD;
      criteria，and qualify for LT.&#xD;
&#xD;
      This study is to compare the impact on survival of neo-adjuvant TAI for patients with beyond&#xD;
      Milan/UCSF Criteria HCC who underwent LT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OS</measure>
    <time_frame>From date of randomization until the date of death from any cause, assessed up to 60 months</time_frame>
    <description>From date of randomization until the date of death from any cause, assessed up to 60 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RFS</measure>
    <time_frame>From date of randomization until the date of recurrence, assessed up to 60 months</time_frame>
    <description>recurrence-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recurrence rate</measure>
    <time_frame>1 year, 2 year, 3 year, 5 year after surgery</time_frame>
    <description>recurrence rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>From date of randomization until the date of progression, assessed up to 60 months</time_frame>
    <description>progression free survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no neo-adjuvant treatment before operation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)</intervention_name>
    <description>TAI</description>
    <arm_group_label>treatment group</arm_group_label>
    <other_name>TAI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. older than 18 years old and younger than 75 years listed for liver transplant;&#xD;
&#xD;
          2. ECOG PS≤1;&#xD;
&#xD;
          3. Child-Pugh Stage A or B&#xD;
&#xD;
          4. Proven hepatocellular carcinoma according patological examination or EASL/AASLD&#xD;
             diagnostic criteria;&#xD;
&#xD;
          5. Not previous treated for tumor;&#xD;
&#xD;
          6. The tumor was diagnosed beyond Milan criteria or University of San Francisco criteria&#xD;
             for LT&#xD;
&#xD;
          7. No distant metastasis;&#xD;
&#xD;
          8. The lab test could meet:&#xD;
&#xD;
             Neutrophil count≥2.0×109/L; Hemoglobin≥100g/L; Platelet count≥75×109/L; Serum&#xD;
             albumin≥35g/L; Total bilirubin&lt;2-times upper limit of normal; ALT&lt;3-times upper limit&#xD;
             of normal; AST&lt;3-times upper limit of normal; Serum creatine&lt;1.5-times upper limit of&#xD;
             normal; PT≤upper limit of normal plus 4 seconds; INR≤2.2;&#xD;
&#xD;
          9. Sign up consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cannot tolerate TAI or LT;&#xD;
&#xD;
          2. Distant metastasis exits;&#xD;
&#xD;
          3. Known history of other malignancy;&#xD;
&#xD;
          4. Be allergic to related drugs;&#xD;
&#xD;
          5. Be treated before (interferon included);&#xD;
&#xD;
          6. Known history of HIV infection;&#xD;
&#xD;
          7. Known history of drug or alcohol abuse;&#xD;
&#xD;
          8. Have GI hemorrhage or cardiac/brain vascular events within 30 days;&#xD;
&#xD;
          9. Pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beicheng Sun, PhD，MD</last_name>
    <role>Study Chair</role>
    <affiliation>Nanjing University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenjie Zhang, PhD</last_name>
    <phone>+86136221584216</phone>
    <email>drzhangwj@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nanjing Drum tower hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beicheng Sun, Phd,MD</last_name>
      <phone>+8613776413940</phone>
      <email>sunbc@nju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</investigator_affiliation>
    <investigator_full_name>Beicheng Sun</investigator_full_name>
    <investigator_title>Director, Hepatobiliary Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

